MMP-1 serum levels predict coronary atherosclerosis in humans by Lehrke, Michael et al.
BioMed  Central
Page 1 of 9
(page number not for citation purposes)
Cardiovascular Diabetology
Open Access Original investigation
MMP-1 serum levels predict coronary atherosclerosis in humans
Michael Lehrke*†1, Martin Greif†2, Uli C Broedl1, Corinna Lebherz2, 
Rüdiger P Laubender3, Alexander Becker2, Franz von Ziegler2, Janine Tittus2, 
Maximilian Reiser4, Christoph Becker4, Burkhard Göke1, Gerhard Steinbeck2, 
Alexander W Leber2 and Klaus G Parhofer1
Address: 1Department of Internal Medicine II, University of Munich, Munich, Germany, 2Department of Internal Medicine I, University of Munich, 
Munich, Germany, 3Institute for Medical Informatics, Biometry and Epidemiology (IBE), University of Munich, Munich, Germany and 
4Department of Radiology, University of Munich, Munich, Germany
Email: Michael Lehrke* - Michael.Lehrke@med.uni-muenchen.de; Martin Greif - Martin.Greif@med.uni-muenchen.de; 
Uli C Broedl - Uli.Broedl@med.uni-muenchen.de; Corinna Lebherz - Corinna.Lebherz@med.uni-muenchen.de; 
Rüdiger P Laubender - laubend@ibe.med.uni-muenchen.de; Alexander Becker - Alexander.Becker@med.uni-muenchen.de; Franz von 
Ziegler - Franz.Ziegler@med.uni-muenchen.de; Janine Tittus - Janine.Tittus@med.uni-muenchen.de; 
Maximilian Reiser - Dekan.Reiser@med.uni-muenchen.de; Christoph Becker - Christoph.Becker@med.uni-muenchen.de; 
Burkhard Göke - Burkhard.Goeke@med.uni-muenchen.de; Gerhard Steinbeck - Gerhard.Steinbeck@med.uni-muenchen.de; 
Alexander W Leber - dr_leber@gmx.de; Klaus G Parhofer - Klaus.Parhofer@med.uni-muenchen.de
* Corresponding author    †Equal contributors
Background: Myocardial infarction results as a consequence of atherosclerotic plaque rupture,
with plaque stability largely depending on the lesion forming extracellular matrix components. Lipid
enriched non-calcified lesions are considered more instable and rupture prone than calcified
lesions. Matrix metalloproteinases (MMPs) are extracellular matrix degrading enzymes with plaque
destabilisating characteristics which have been implicated in atherogenesis. We therefore
hypothesised MMP-1 and MMP-9 serum levels to be associated with non-calcified lesions as
determined by CT-angiography in patients with coronary artery disease.
Methods: 260 patients with typical or atypical chest pain underwent dual-source multi-slice CT-
angiography (0.6-mm collimation, 330-ms gantry rotation time) to exclude coronary artery
stenosis. Atherosclerotic plaques were classified as calcified, mixed or non-calcified.
Results: In multivariable regession analysis, MMP-1 serum levels were associated with total plaque
burden (OR: 1.37 (CI: 1.02-1.85); p < 0.05) in a model adjusted for age, sex, BMI, classical
cardiovascular risk factors, hsCRP, adiponectin, pericardial fat volume and medication. Specification
of plaque morphology revealed significant association of MMP-1 serum levels with non-calcified
plaques (OR: 1.16 (CI: 1.0-1.34); p = 0.05) and calcified plaques (OR: 1.22 (CI: 1,03-1.45); p < 0.05)
while association with mixed plaques was lost in the fully adjusted model. No associations were
found between MMP9 serum levels and total plaque burden or plaque morphology.
Conclusion: MMP-1 serum levels are associated with total plaque burden but do not allow a
specification of plaque morphology.
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Introduction
Myocardial infarction is an acute pathological event
which is caused by the rupture of a chronically formed
atherosclerotic lesion. The process of atherosclerosis is ini-
tiated by the entrapment of modified LDL particles in the
subendothelial space of the vessel wall, which causes the
infiltration of immune cells, especially macrophages and
subsequent foam cell formation. Proliferation of vascular
smooth muscle cells (VSMC) and the deposition of extra-
cellular matrix components result in the progression to
more advanced lesions, stigmatized by a fibrous cap over-
laying a lipid enriched atherosclerotic core [1]. Plaque
rupture mostly occurs in the plaques' shoulder region,
which is exposed to high tangential shear stress. The bio-
chemical strength of the fibrous cap thereby depends on
its extracellular matrix composition with fibrillar colla-
gen, especially type I and III, providing structural stability
by cross linkage [2].
Intravascular ultrasound (IVUS) and CT angiography do
now allow the in-vivo detection of outward directed non-
stenosing lesions in addition to the characterisation of
plaque morphology. Lipid enriched, non-calcified lesions
are primarily detected in the coronary system of patients
presenting with unstable angina, suggesting a high rup-
ture susceptibility of these plaques, while fibrous and cal-
cified lesions dominate in patients presenting with stable
angina [3-6]. This concept is supported by autopsy studies
demonstrating impaired structural stability of soft, lipid
enriched plaques in comparison to calcified lesions [7].
Consequently, non-calcified lesions were prospectively
associated with higher coronary event rates [8,9].
Matrix Metalloproteinases (MMPs) are a family of extra-
cellular matrix degrading enzymes which have been
implicated in plaque destabilisation [10]. MMPs are
expressed by macrophages, VSMC and endothelial cells in
response to inflammatory stimuli. MMP-1 and MMP-9 are
primarily detected in the vulnerable shoulder region and
areas of foam cell formation in the atherosclerotic plaques
[10,11] where they colocalize with degraded collagen
fragments [11]. While MMP-1 cleaves intact fibrillar inter-
stitial collagen, especially type I and III, MMP-9 has prom-
inent activity against basement membrane components
including type IV collagen, laminin and elastin [12]. Con-
sistently, polymorphisms of the MMP-1 and -9 genes were
linked to complicated coronary lesions and atherosclero-
sis in epidemiological studies [13,14].
We therefore hypothesized MMP-1 and MMP-9 serum lev-
els to predict the presence of non-calcified, lipid enriched
plaques as determined by CT angiography in a cohort of
260 patients with typical or atypical chest pain.
Methods
Ascertainment of Subjects
As described previously [15], 260 patients with typical or
atypical chest pain underwent dual-source CT-coronary
angiography for exclusion of coronary artery stenosis dur-
ing a period of 20 months from March 2006 till October
2007. Study subjects were asked to complete a brief ques-
tionnaire and had blood drawn after providing written
informed consent. The study protocol was approved by
the Ethics Committee of the Ludwig-Maximilians-Univer-
sity Munich, Germany.
Dual-source CT image analysis
CT-coronary angiography was performed as described
previously [15], using a Siemens Definition scanner (Sie-
mens Medical Solutions, Forchheim, Germany). Briefly,
DSCT datasets were evaluated by two independent inves-
tigators using a dedicated cardiac workstation (Siemens,
Leonardo Circulation). Atherosclerotic plaques were clas-
sified as calcified, mixed or non-calcified lesions. Calcified
plaques were defined as lesions with a HU value above
130 while non-calcified plaques were defined as structures
clearly assignable to the vessel wall (in at least two views)
with densities less than the lumen contrast. Mixed plaques
where defined by < 50% plaque calcified area. The coro-
nary tree was segmented according to the suggestions of
the AHA into a 15 segment model. Each segment was fur-
ther divided into a proximal and a distal segment. Each
segment was then classified as containing either calcified,
non-calcified, mixed or no plaque. Based on the number
of diseased segments a plaque score was calculated.
Pericardial fat assessment was performed as described pre-
viously using the Volume analysis software tool of the Sie-
mens Leonardo Circulation workstation [16].
Laboratory procedures
Blood samples were stored at -70°C until analysis. Serum
levels of MMP-1 and MMP-9 were determined using a
commercial enzyme-linked immunosorbent assay (R&D,
Wiesbaden, Germany) following the manufacturer's
instruction. Intra- and interassay coefficients of variance
derived from a pooled human plasma sample measured
in triplicate on each plate were 4.1% and 6.7% for MMP-
1 and 3.5% and 5.9% for MMP-9. Adiponectin serum lev-
els were assessed by enzyme-linked immunosorbent assay
(R&D, Wiesbaden, Germany) as described earlier [15].
Plasma total cholesterol, LDL-cholesterol (LDL-C), HDL-
cholesterol (HDL-C) and triglycerides were measured by
routine enzymatic methods. Determination of high sensi-
tivity C-reactive protein (hsCRP) levels was performed at
the Department of Clinical Chemistry (Campus
Grosshadern, University of Munich, Germany).Cardiovascular Diabetology 2009, 8:50 http://www.cardiab.com/content/8/1/50
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Statistical Analysis
Statistical analyses were performed using SPSS 16 and R
(version 2.8.1) software. (R Development Core Team
(2008). R: A language and environment for statistical
computing. R Foundation for Statistical Computing,
Vienna, Austria. ISBN 3-900051-07-0, URL http://www.R-
project.org.)
Data are reported as proportions or median (interquartile
range). Spearman correlation was perfomed as appropri-
ate to evaluate unadjusted associations between MMP-1
or MMP-9 and other variables. A generalized linear regres-
sion model (logistic regression) based on complete cases
for all covariables was used to assess the association
between MMP-1 and MMP-9 serum levels with total
plaque burden or the presence of calcified-, mixed- or
non-calcified plaques adjusted for age, sex, body mass
index (BMI), diabetes, hypertension, family history of cor-
onary artery disease, smoking, LDL-C, HDL-C, triglycer-
ides, hsCRP levels, adiponectin levels, medical treatment
(statin, ACE inhibitors, angiotensin-receptor blockers,
diuretics, ASS, Clopidogrel, Phenprocoumon) and peri-
cardial adipose tissue volume.
Results
The baseline characteristic of the study sample is pre-
sented in Table 1. Representative images of different
plaque morphologies as detected by CT-angiography are
shown in Figure 1.
Association of MMP-1 and MMP-9 serum levels with 
cardiovascular risk factors and coronary atherosclerosis
MMP-1 and MMP-9 were found to correlate positively to
the inflammatory marker hsCRP (MMP-1, r = 0.194, p <
0.001; MMP-9, r = 0.173, p = 0.005) and to each other (r
= 0.269; p < 0.001) (Table 2). In addition, positive corre-
Table 1: Characteristics of the study population:
Characteristics: n = 260
Age (yrs) 63 (54 - 69)
Men (%) 66.8
Classical CV-Risk Factors (%)
Diabetes* 6.2
Hypertension* 47.3
Family history of CAD** 26.9
Smoking** 15
Body Mass Index (kg/m2) 26.2 (24.2 - 29.3)
Laboratory profile
Total cholesterol (mg/dl) 209 (181.2 - 239)
LDL cholesterol (mg/dl) 125 (96.7 - 151)
HDL cholesterol (mg/dl) 52 (44 - 60)
Triglycerides (mg/dl) 141 (103 - 197.5)
C-reactive protein (mg/dl) 0.23 (0 - 0.53)
Adiponectin (ug/ml) 5.05 (3.25 - 7.67)
MMP-1 (ng/ml) 3.91 (2.24 - 5.67)
MMP-9 (ng/ml) 211.3 (147.1 - 283)
Medical treatment (%)***
Statin 37.7
Anticoagulation/Antiplatelet 63.5
Betablocker 64.9
ACE-I or ARB 51.8
Diuretics 30.6
CT data
Pericardial adipose tissue in volume (ml)§ 184.1 (128.6 - 255.8)
Number of coronary artery plaques (total)§§ 3 (1 - 6)
Number of calcified plaques (154 patients) 1 (0 - 3)
Number of mixed plaques (102 patients) 0 (0 - 1)
Number of non-calcified plaques (126 patients) 0 (0 - 2)
Anticoagulation: Aspirin, Clopidogrel, Phenprocoumon
Values are presented as proportions or median (interquartile range). Minimum/maximum values are presented for plaque data. No plaques were 
found in 51 patients.
* history of hypertension and diabetes is known in 236 patients
** history of smoking and family history of CAD is known in 235 patients
*** medical treatment is known in 222 patients
§adequate image quality for evaluation of PAT was obtained in 248 patients
§§ adequate image quality for evaluation of coronary plaques was obtained in 242 patientsCardiovascular Diabetology 2009, 8:50 http://www.cardiab.com/content/8/1/50
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lation of both MMPs were found with serum triglycerides
(MMP-1, r = 0.195, p = 0.002; MMP-9, r = 0.135, p =
0.03), while only MMP-9 correlated to BMI (r = 0.149; p
= 0.02) and pericardial adipose tissue volume (r = 0.253;
p < 0.001) (Table 2). '
MMP-1 but not MMP-9 serum levels correlated with total
plaque burden (r = 0.16; p = 0.013) in addition to non-
calcified lesions (r = 0.157; p = 0.014) (Figure 2, Table 2).
No associations of either parameter were found with age,
sex, total cholesterol, LDL-cholesterol, HDL-cholesterol,
adiponectin, classical cardiovascular risk factors or medi-
cation, although patients receiving betablockers had
lower MMP-9 levels (p = 0.049)(Table 2).
MMP-1 serum level predict total plaque burden
In multivariable logistic regression analysis MMP-1 serum
levels were associated with total plaque burden in a sim-
ple model adjusting for age, sex, BMI (OR 1.28 (CI: 1.02
to 1.59; p < 0.05) as well as in more complex models
adjusting for all covariables (age, sex, BMI, classical cardi-
ovascular risk factors, hsCRP, adiponectin, pericardial fat
volume, medication) (OR 1.37 (CI: 1.02 to 1.85; p < 0.05)
(Table 3). No association of MMP-9 was found with total
plaque burden (Table 3).
MMP-1 serum levels predict calcified and non-calcified 
lesions
To further evaluate the relevance of MMP-1 and MMP-9
serum levels to predict the presence of calcified, mixed or
non-calcified plaques, a multivariable logistic regression
analysis was performed for each parameter. Positive asso-
ciation of MMP-1 serum levels were found with calcified
(OR 1.22 (CI: 1.04 to 1.43; p < 0.05), mixed (OR 1.19 (CI:
1.03 to 1.38; p < 0.049), and non-calcified lesions (OR
1.19 (CI: 1.04 to 1.37; p < 0.05) after adjusting for age,
sex, BMI and classical cardiovascular risk factors (Table 4).
This association remained significant for calcified (OR
1.22 (CI: 1.03 to 1.45; p < 0.05) and non-calcified (OR
1.16 (CI: 1.0 to 1.34; p = 0.05) lesions after further adjust-
ment for hsCRP, adiponectin, pericardial fat volume and
medication but was lost for mixed lesions (Table 4). No
association was found between MMP-9 serum levels and
non-calcified, mixed or calcified lesions.
Discussion
In this study we report a positive association of MMP-1
serum levels with total plaque burden in a population of
260 patients who underwent CT-angiography for exclu-
sion of coronary artery disease.
We thereby found MMP-1 serum levels to associate with
calcified lesions and non-calcified lesions after adjust-
ment for age, sex, BMI, classical cardiovascular risk factors,
hsCRP, adiponectin, pericardial fat volume and medica-
tion. MMP-1 serum levels were further associated with
mixed lesions in reduced statistical models, which was
however lost after adjustment for all covariables.
Clinical risk management of cardiovascular disease would
greatly benefit from event stratifying biomarkers. The rup-
ture prone atherosclerotic plaque is histologically defined
by a thin fibrous cap overlaying a lipid enriched atherom-
Representative images of calcified (a), mixed (b) and non-calcified plaques (c) as detected by CT-angiography Figure 1
Representative images of calcified (a), mixed (b) and non-calcified plaques (c) as detected by CT-angiography.
c) non-calcified
plaque
b) mixed plaque a) calcified plaque
Figure 1:Cardiovascular Diabetology 2009, 8:50 http://www.cardiab.com/content/8/1/50
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atous core [1]. Non-calcified, lipid enriched plaques have
primarily been found in patients presenting with acute
coronary syndrome and unstable angina, while mixed or
calcified lesions dominated in patients with stable angina
[3-6]. Consequently, non-calcified plaques were prospec-
tively associated with increased coronary event rates [8,9],
and short term tendency for plaque volume progression
[17]. Non-calcified plaques have therefore been consid-
ered to be more prone to rupture than calcified lesions.
Consistently, we did find MMP-1 serum levels to be posi-
tively associated with non calcified lesions, however, sim-
ilar associations were found with calcified- and to a lesser
extent with mixed lesions, resulting in a positive associa-
tion of MMP-1 serum levels with total plaque burden
without discriminative power for a specific plaque mor-
phology.
Evidence for plaque destabilising characteristics of MMP-
1 has been created by its accumulation in the vulnerable
shoulder region of thin capped, lipid enriched plaques
Table 2: Correlation of Serum MMP-1 and MMP-9 levels with cardio vascular risk factors and plaque morphology
MMP-1 MMP-9
Median (IQR) P Median (IQR) P
Rho Rho
Age -0.003 0.97 0.004 0.50
Sex
- female 4.46 (2.24 - 5.69) 0.6 207 (137-169) 0.16
- male 3.38 (2.12 - 5.52) 220 (160-288)
BMI 0.025 0.69 0.149 0.018
Diabetes mellitus: Yes 4.34 (2.99 - 5.82) 0.60 243.2 (189.9-354.1) 0.89
No 3.78 (2.09 - 5.67) 209.6 (144.8-277.2)
Hypertension: Yes 3.74 (2.10 - 5.82) 0.89 212.7 (150.1 - 288.1) 0.67
No 3.96 (2.23 - 5.67) 195.6 (135.5 - 266.9)
Family history of CAD: Yes 3.73 (1.80 - 5.64) 0.45 195.6 (140.4 - 268.4) 0.15
No 3.93 (2.24 - 5.69) 212.4 (148.1 - 287.5)
Smoking: Yes 4.08 (1.90 - 5.70) 0.86 185.6 (133.6 - 283.2) 0.97
No 3.73 (2.24 - 5.67) 212.3 (146.0 - 275.8)
Statin treatment: Yes 4.11 (2.44 - 5.90) 0.25 205.2 (138.8 - 284.1) 0.44
No 3.52 (2.09 - 5.65) 212.3 (153.7 - 280.6)
Anticoagulation: Yes 3.71 (2.18 - 5.65) 0.32 180.9 (137.0 - 257.5) 0.06
No 3.67 (2.02 - 5.61) 235.0 (157.6 - 313.5)
Betablocker: Yes 3.91 (2.44 - 5.23) 0.80 206.5 (139.5 - 273.5) 0.049
No 3.48 (2.07 - 6.07) 217.8 (158.5 - 339.3)
ACE-I or ARB: Yes 4.11 (2.44 - 5.65) 0.51 207.6 (144.7 - 283.2) 0.66
No 3.5 (2.09 - 5.82) 210.3 (153.7 - 282.3)
Diuretics: Yes 4.06 (2.90 - 5.59) 0.32 211.8 (141.3 - 300.0) 0.76
No 3.6 (2.07 - 5.79) 209.6 (151.1 - 276.9)
Pericardial adipose tissue 0.068 0.28 0.253 <0.0001
Adiponectin -0.111 0.08 -0.084 0.18
High-sensitivity CRP 0.194 0.001 0.173 0.005
Triglycerides 0.195 0.002 0.135 0.028
Total-cholesterol 0.041 0.52 -0.037 0.53
LDL-cholesterol -0.002 0.97 -0.049 0.43
HDL-cholesterol -0.048 0.45 -0.018 0.77
MMP-1 0.269 <0.0001
Total-Plaque burden 0.16 0.013 0.087 0.17
Non-Calcified Plaques 0.157 0.014 0.002 0.98
Mixed Plaques 0.119 0.07 0.12 0.06
Calcified Plaques 0.118 0.07 0.058 0.37
Median (IQR) or Spearman correlation coefficient are presented. (CAD: Coronary artery disease)Cardiovascular Diabetology 2009, 8:50 http://www.cardiab.com/content/8/1/50
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and its co-localization with degraded collagen fragments
[10,11]. In addition, increased serum levels of MMP-1
have been found in patients with coronary artery disease
in some [18,19], but not all studies [20], with highest lev-
els being present in patients with unstable angina [21].
The positive association of MMP-1 serum levels with total
plaque burden as reported in our study therefore supports
the concept of MMP-1 being significantly released from
atherosclerotic plaques. The missing discriminative power
of MMP-1 serum levels for a specific plaque morphology
however suggests MMP-1 to be similarly present within all
plaques, independent of their morphology, questioning
its relevance as a major plaque destabilizing factor. Alter-
natively, non-calcified lesions as determined by CT-angi-
ography might not sufficiently identify the rupture prone
vulnerable lesion. CT-angiography has been reported to
provide a diagnostic sensitivity of 82 to 84% and specifi-
city of 88 to 91% in comparison to IVUS as the gold stand-
ard [22,23]. Highest diagnostic accuracy was found for
calcified lesions (sensitivity 94% to 95%; specificity 92%
to 94%), while non-calcified lesions were detected with a
diagnostic sensitivity of 78% by our group in a previous
study and 53% by Achenbach et al. [22,23]. In addition,
CT-angiography has limited capacities to further subdi-
vide non-calcified lesions in fibrous and lipid enriched
plaques. CT-angiography therefore provides an advanced
non-invasive diagnostic tool for the detection of coronary
plaques, which however still holds modest limitations in
the detection of non-calcified lesions. We can not rule out
that this might have affected the presented results.
MMP-1 and MMP-9 are primarily expressed by macro-
phages and smooth muscle cells in response to a variety of
proatherogenic stimuli including sheer stress, oxidized
LDL and inflammatory cytokines [10]. Consistently, cir-
culating MMP-1 levels have been associated with athero-
sclerotic plaque inflammation as detected by 18F-FDG-
PET/CT [18]. In agreement with their proinflammatory
regulation we found both MMPs to correlate positively
with the inflammatory marker hsCRP. Our study there-
fore supports the concept of an inflammatory microenvi-
ronement characterising the atherosclerotic plaque which
potentially could reflect plaque macrophage content. In
contrast to other studies we could not ascribe highest
inflammatory activity to non-calcified lesions [24,25].
Future studies are needed to characterise plaque morphol-
ogy dependent inflammation in-vivo, preferentially by
combining CT-Angiography with 18F-FDG-PET.
Surprisingly, we did not find associations between MMP-
9 serum levels and total plaque burden or plaque mor-
phology. This agrees with some reports [26,27] but con-
Correlation between MMP-1 serum levels and total plaque  burden Figure 2
Correlation between MMP-1 serum levels and total 
plaque burden.
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Table 3: Multivariate Association of MMP-1 and MMP-9 serum levels and total plaque burden as assessed by CT-angiography
Total Plaque MMP-1 MMP-9
Adjusted for OR (CI) P value OR (CI) P value
Age, Gender, BMI 1.28 (1.02 to 1.59) 0.031 0.97 (0.90 to 1.05) 0.49
Age, Gender, BMI, RF* 1.30 (1.01 to 1.66) 0.040 0.96 (0.90 to 1.03) 0.29
Age, Gender, BMI, RF*, CRP 1.29 (1.00 to 1.67) 0.044 0.96 (0.90 to 1.03) 0.28
Age, Gender, BMI, RF*, CRP, AD, PCF 1.32 (1.01 to 1.72) 0.040 0.97 (0.90 to 1.03) 0.32
Age, Gender, BMI, RF*, CRP, AD, PCF, Med 1.37 (1.02 to 1.85) 0.037 0.98 (0.90 to 1.06) 0.63
Odds ratio and 95% CI increase in plaque quantity for 1 ng/ml (MMP-1) and 20 ng/ml (MMP-9) raise in serum levels are presented.
*Risk factors (RF*) included LDL-cholesterol, HDL-cholesterol, triglycerides, cigarette smoking, hypertension, diabetes, family history for CVD.
Abbreviations: CRP (hsCRP), AD (adiponectin), PCF (pericardial fat volume), Med (medication)Cardiovascular Diabetology 2009, 8:50 http://www.cardiab.com/content/8/1/50
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trasts to others, which found incremental MMP-9 serum
levels in patients with coronary artery disease [28,29]. The
reason for this discrepancy is not clear but might be
related to different patient populations and a differential
assessment of atherosclerosis. CT angiography as used in
our study allows the assessment of non-stenosing, out-
ward directed lesions of the vessel wall and is not limited
to the detection of stenosing lesions as assessed by coro-
nary angiography [30].
Interestingly and consistent with others we found positive
association between MMP-9 serum levels and BMI
[31,32], in addition to pericardial fat volume and serum
triglyceride concentrations, suggesting adipose tissue to
be a significant determinant of circulating MMP-9 levels.
Our study has several limitations. Detection of coronary
plaques quantity and morphology by CT-angiography
does not provide the diagnostic accuracy of IVUS as the
gold standard. The presented results are associative and
can not prove causal relationship between MMP-1 serum
levels and atherosclerotic plaque quantity or morphology.
In addition, the cross sectional study design did not allow
an evaluation of clinical relevance with respect to future
cardiac event rates. Future studies are needed to confirm
our findings in larger patient cohorts possibly by applying
a prospective study design.
In conclusion we found MMP-1 serum levels to be an
independent predictor for coronary atherosclerotic
lesions, while not allowing a stratification of plaque mor-
phology.
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